High-throughput cancer stem cell-based screening assay for therapeutic compounds

by Alexey Bersenev on August 19, 2010 · 0 comments

in cancer

Post to Twitter Send Gmail Post to LinkedIn

Therapeutic targeting of cancer stem cells can be investigated by screening of chemical or small molecule compounds library. The show case study came up a year ago and demonstrated feasibility of this approach.

Recent study, published in EMBO Molecular Medicine, extends this approach to neuroblastoma in children.

Here, we describe a strategy to identify compounds that selectively target patient-derived cancer stem cell-like tumour-initiating cells (TICs) while sparing normal paediatric stem cells (skin-derived precursors, SKPs) and characterize two therapeutic candidates.

Methodologically, tested cancer stem cell line was derived from bone metastases of neuroblastoma (NB) patient:

NB TICs cultured from bone marrow metastases of a multiple-relapse NB patient (NB12) were treated with 4383 compounds from the LOPAC1280â„¢ compound library, the Prestwick Chemical Library and the Spectrum Collection. Normal human paediatric SKP cells (FS90) were tested in parallel as a counterscreen to identify compounds that are selectively cytotoxic or cytostatic against NB TICs.

I think, companies should pick up this kind of approach for in vitro and in vivo high-throughput screening for new anti-cancer drugs.

You can find the article in open access.

Also watch: Lecture: Mickie Bhatia – Stem cell based high-throughput screening for small molecules and drugs

{ 0 comments… add one now }

Leave a Comment

Previous post:

Next post: